Prasugrel to lead Japan-origin blockbusters
This article was originally published in Scrip
Now with a key US approval recommendation under its belt, Daiichi Sankyoand Lilly's novel antiplatelet agent prasugrel (Effient) is set to reap peak global annual sales of $2.5 billion. Sales in Japan, where the product is still in Phase II development, could reach ¥40 billion ($438.6 million) a year, a new Japanese analysis predicts.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.